Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM2B | Q8NHM5 | 5/20 | 0.62 |
| ▸ | CES2 | O00748 | 1/20 | 0.61 |
| ▸ | CES1 | P23141 | 1/20 | 0.61 |
| ▸ | PARP1 | P09874 | 1/20 | 0.57 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.56 |
| ▸ | MGLL | Q99685 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 4/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.53 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31636008 | 0.93 | CES2 (0.65) | KDM2BCES2CES1PARP1HSD11B1 | |
| SCHEMBL7309424 | 0.93 | CES2 (0.65) | KDM2BCES2CES1PARP1HSD11B1 | |
| SCHEMBL6208933 | 0.87 | CES2 (0.57) | KDM2BCES2CES1PARP1HSD11B1 | |
| Hydrochloric Acid SCHEMBL16432038 | 0.86 | HTR2C (0.57) | KDM2BCES2CES1PARP1HSD11B1 | |
| SCHEMBL30771226 | 0.84 | MGLL (0.62) | KDM2BCES2CES1PARP1HSD11B1 | |
| SCHEMBL5210032 | 0.84 | MGLL (0.62) | KDM2BCES2CES1PARP1HSD11B1 | |
| SCHEMBL4772361 | 0.84 | KDM2B (0.54) | KDM2BCES2CES1PARP1HSD11B1 | |
| Hydrochloric Acid SCHEMBL17913736 | 0.83 | KDM2B (0.53) | KDM2BCES2CES1PARP1HSD11B1 | |
| SCHEMBL200723 | 0.82 | KDM2B (0.58) | KDM2BMEN1KMT2APOLBNPC1 | |
| SCHEMBL14638260 | 0.82 | MGLL (0.66) | KDM2BCES2CES1HSD11B1MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024059745-A2 | N-METHYL-D-ASPARTATE RECEPTOR (NMDAR) ANTAGONISTS AND USES THEREOF | BEXSON BIOMEDICAL, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| EP-3112873-B1 | METHOXETAMINE ASSAY | RANDOX LABORATORIES LTD (GB) | 2021-11-24 | — | — | EP | disclosed |
| WO-2019077332-A1 | THERAPEUTIC COMPOUNDS | SMALL PHARMA LTD (GB) | 2019-04-25 | — | — | WO | disclosed |
| WO-2019077332-A1 | THERAPEUTIC COMPOUNDS | SMALL PHARMA LTD (GB) | 2019-04-25 | — | — | WO | disclosed |
| US-10254297-B2 | Assay for methoxetamine | RANDOX LABORATORIES LTD. (GB) | 2019-04-09 | — | — | US | disclosed |
| US-20170003308-A1 | ASSAY FOR METHOXETAMINE | NORTHERN BANK LIMITED (IE) | 2017-01-05 | — | — | US | disclosed |
| EP-3112873-A1 | METHOXETAMINE ASSAY | Randox Laboratories Ltd. (GB) | 2017-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10254297-B2 | Assay for methoxetamine | PNMT, INMT, HNMT | KDM2B 177/4885CES2 210/4885CES1 909/4885 |
| US-20170003308-A1 | ASSAY FOR METHOXETAMINE | PNMT, INMT, HNMT | KDM2B 177/4885CES2 210/4885CES1 909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.